Yabao Pharmaceutical Group Co Ltd (600351) — Cash Flow-to-Debt Ratio
Yabao Pharmaceutical Group Co Ltd (600351) has a Cash Flow-to-Debt Ratio of 0.22x as of September 2025, meaning its operating cash flow of CN¥129.49 Million could theoretically repay 0% of its total liabilities (CN¥585.77 Million) in one year. See Yabao Pharmaceutical Group Co Ltd (600351) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Yabao Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2001–2024)
Historical debt coverage capacity for Yabao Pharmaceutical Group Co Ltd across 24 annual periods. For the full cash flow conversion analysis, see Yabao Pharmaceutical Group Co Ltd (600351) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Yabao Pharmaceutical Group Co Ltd (2001–2024)
Year-by-year debt coverage analysis for Yabao Pharmaceutical Group Co Ltd. Check earnings quality score of Yabao Pharmaceutical Group Co Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.73x | CN¥471.69 Million | CN¥649.02 Million | ▲ +25.7% |
| 2023 | 0.58x | CN¥497.55 Million | CN¥860.33 Million | ▲ +41.2% |
| 2022 | 0.41x | CN¥460.46 Million | CN¥1.12 Billion | ▲ +4.2% |
| 2021 | 0.39x | CN¥437.50 Million | CN¥1.11 Billion | ▲ +23.4% |
| 2020 | 0.32x | CN¥380.96 Million | CN¥1.20 Billion | ▲ +19.0% |
| 2019 | 0.27x | CN¥425.17 Million | CN¥1.59 Billion | ▲ +13.8% |
| 2018 | 0.24x | CN¥426.60 Million | CN¥1.81 Billion | ▲ +111.5% |
| 2017 | 0.11x | CN¥161.73 Million | CN¥1.45 Billion | ▲ +5.2% |
| 2016 | 0.11x | CN¥155.95 Million | CN¥1.48 Billion | ▲ +16.0% |
| 2015 | 0.09x | CN¥143.47 Million | CN¥1.57 Billion | ▼ -30.3% |
| 2014 | 0.13x | CN¥178.63 Million | CN¥1.37 Billion | ▲ +247.0% |
| 2013 | 0.04x | CN¥56.80 Million | CN¥1.51 Billion | ▲ +149.5% |
| 2012 | -0.08x | CN¥-96.73 Million | CN¥1.27 Billion | ▼ -308.1% |
| 2011 | 0.04x | CN¥40.73 Million | CN¥1.11 Billion | ▲ +181.9% |
| 2010 | 0.01x | CN¥18.57 Million | CN¥1.43 Billion | ▼ -95.4% |
| 2009 | 0.28x | CN¥368.56 Million | CN¥1.31 Billion | ▲ +130.6% |
| 2008 | 0.12x | CN¥102.90 Million | CN¥843.93 Million | ▼ -19.9% |
| 2007 | 0.15x | CN¥105.69 Million | CN¥694.23 Million | ▲ +787.5% |
| 2006 | 0.02x | CN¥11.59 Million | CN¥675.74 Million | ▼ -49.3% |
| 2005 | 0.03x | CN¥26.40 Million | CN¥780.42 Million | ▼ -74.6% |
| 2004 | 0.13x | CN¥79.73 Million | CN¥599.65 Million | ▲ +579.1% |
| 2003 | -0.03x | CN¥-9.62 Million | CN¥346.67 Million | ▼ -119.4% |
| 2002 | 0.14x | CN¥24.29 Million | CN¥169.57 Million | ▲ +3.0% |
| 2001 | 0.14x | CN¥23.59 Million | CN¥169.58 Million | — |